View Older Stories View More Recent Stories
-
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following l
-
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
-
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
-
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
-
Aytu BioPharma launches EXXUA for major depressive disorder treatment
-
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
-
Aytu Biosciences (AYTU) PT Raised to $13 at Ascendiant Capital
-
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
-
Aytu BioScience (AYTU) Tops Q1 EPS by 21c
-
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
-
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
-
Aytu BioPharma receives patent extension for EXXUA through 2030
-
Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)
-
Aytu BioPharma to Present at Upcoming October 2025 Conferences
-
Aytu BioPharma to Present at Upcoming September 2025 Conferences
-
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)
-
Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
-
Lake Street Capital Markets Starts Aytu Biosciences (AYTU) at Buy
-
Ascendiant Capital Starts Aytu Biosciences (AYTU) at Buy
-
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)
-
Aytu BioScience (AYTU) Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA
-
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)
-
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opp
-
Aytu BioScience (AYTU) Prices Upsized 9.6M Share Offering at $1.50/sh
-
Aytu BioScience (AYTU) Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA
-
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
-
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States
-
Aytu BioScience (AYTU) Tops Q1 EPS by 65c
-
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results
-
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025
-
Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
-
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
-
Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025
-
Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
-
Aytu BioPharma Disclosure Notification
-
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)
-
Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results
-
Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024
-
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
-
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
-
Aytu BioScience (AYTU) Announces Exclusive Agreement with Lupin Pharma Canada to Commercialize Adzenys XR-ODT and Cotempla XR-ODT
-
Aytu BioScience (AYTU) Files $100M Mixed Shelf
-
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
-
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
-
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024
-
Aytu BioScience (AYTU) Sells Consumer Health Business Following Wind Down of Consumer Health Operations
-
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
-
Aytu BioScience (AYTU) Announces Paydown and Refinancing of Term Loan
-
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
